BUZZ-Alnylam, Ionis fall as heart-drug data raise doubts over combination treatment
ALNY•Year-to-date performance
- As of last close, ALNY down 40.5%, IONS down 21.1% YTD
Shares fall after detailed heart-drug data
-
Shares of Alnylam Pharmaceuticals ALNY.O fall 5.3% to $224, while those of Ionis Pharmaceuticals IONS.O fall 1.3% to $61.62 in premarket trading
-
Detailed data presented at the ESC Congress showed AstraZeneca AZN.L and Ionis' experimental drug eplontersen provided no added benefit in patients already taking Pfizer's PFE.N tafamidis for a deadly heart condition caused by abnormal protein buildup
Study missed main goal, but showed possible benefit alone
-
The overall study missed its main goal of reducing cardiovascular deaths and recurring heart problems, as previously disclosed in July, although eplontersen showed a possible benefit when used alone
-
RBC says the findings weaken the case for seeking approval of eplontersen for the heart condition, weighing on Ionis shares
